Practical guidance on the clinical management of belantamab mafodotin for patients with relapsed/refractory multiple myeloma: Recommendations from the Middle East and North Africa expert panel

Belantamab mafodotin demonstrates significant efficacy for relapsed/refractory multiple myeloma but is associated with high-frequency ocular adverse events (OAEs). These OAEs are manageable through dose delays and modifications, with screening reducing their impact. Regional experts from the Middle East and North Africa developed practical recommendations for OAE identification and management, focusing on preventing severe ocular events.